肝癌患者介入治疗前后血清可溶性CD105水平对比研究  

Clinical study on serum soluble CD105 of patients with primary liver carcinoma before and after interventional therapy

作　　者：梁卫明[1] 陈义雄[1] 陈国强[1] 谢锐[2] 李双齐[3] 

机构地区：[1]广东医学院附属医院,湛江524001 [2]广东医学院,湛江524000 [3]大庆龙南医院普外科12病区,黑龙江163000

出　　处：《齐齐哈尔医学院学报》2013年第13期1878-1879,共2页Journal of Qiqihar Medical University

摘　　要：目的探讨原发性肝癌患者介入治疗前后血清可溶性CD105水平的变化及其临床应用价值。方法采用酶联免疫吸附试验法(ELISA)检测32例正常人以及66例原发性肝癌患者血清可溶性CD105水平,并比较22例原发性肝癌患者介入治疗前后血清可溶性CD105水平。结果原发性肝癌患者血清可溶性CD105水平明显高于正常对照组(P<0.01),血清可溶性CD105水平与临床分期有关、与原发性肝癌患者性别、年龄、病理类型无关;Ⅲ期明显高于Ⅱ期(P<0.01),Ⅱ期明显高于Ⅰ期(P<0.01),Ⅰ期明显高于正常对照组(P<0.01);介入治疗后原发性肝癌患者血清可溶性CD105水平明显低于介入治疗前(P<0.01)。结论血清可溶性CD105可能与原发性肝癌的发生发展有关,血清可溶性CD105检测有可能成为原发性肝癌疗效监测和预后判断的观察指标。Objective To investigate the changes of serum soluble CD105 in patients with primary livercarcinoma（PLC） pre-and post-interventional therapy and its clinical value.Methods Enzyme linked immunosorbent assay（ELISA） were available to detect the level of serum soluble CD105 in 66 cases of patients with PLC and 32 cases of normal control subject,compared with 22 patients with PLC pre-and post-interventional therapy.Results The level of serum soluble CD105 were elevated in all subgroups of patients with PLC compared to the controls（P0.01）,serum soluble PLC was correlated with clinical stage,and not with sex,age and pathologic types;the serum soluble CD105 level in stage Ⅲ was higher in comparison with stage Ⅱ（P0.01）,in stage Ⅱ it was higher than in stage Ⅰ and normal control subject（P0.01）,and in stage Ⅰ it was higher than in normal control subject（P0.01）,that the serum soluble CD105 levels were remarkably reduced in patients with PLC after interventional therapy（P0.01）.Conclusions These results suggest that serum soluble CD105 may be involved in the occurrence and development of PLC,determination of CD105 may be used as a predict prognosis,evaluation of disease marker for PLC.

关 键 词：CD105 原发性肝癌 介入治疗 

分 类 号：R512.62[医药卫生—内科学]